Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7412041 | 1.00 | ALOX5AP (0.50) | ALOX5APFEN1F2RL3CHRNB4CHRNA3 | |
| SCHEMBL21845257 | 1.00 | ALOX5AP (0.50) | ALOX5APFEN1F2RL3CHRNB4CHRNA3 | |
| SCHEMBL7415126 | 0.88 | CHRNB2 (0.61) | ALOX5APFEN1F2RL3CHRNB4CHRNA3 | |
| SCHEMBL27082603 | 0.87 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL1241581 | 0.86 | F2RL3 (0.47) | ALOX5APFEN1F2RL3CHRNB4CHRNA3 | |
| SCHEMBL1240615 | 0.86 | F2RL3 (0.47) | ALOX5APFEN1F2RL3CHRNB4CHRNA3 | |
| SCHEMBL2200803 | 0.86 | ALOX5AP (0.50) | ALOX5APFEN1F2RL3 | |
| SCHEMBL1240503 | 0.85 | ALOX5AP (0.47) | ALOX5APFEN1F2RL3CHRNB4CHRNA3 | |
| SCHEMBL1240512 | 0.85 | F2RL3 (0.46) | ALOX5APFEN1F2RL3CHRNB4CHRNA3 | |
| SCHEMBL1240500 | 0.85 | ALOX5AP (0.47) | ALOX5APFEN1F2RL3CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-112996795-B | Fused tricyclic derivatives as SRC homo-2 phosphatase inhibitors | 尼坎治疗公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-113227103-B | Trisubstituted heteroaryl derivatives as SRC homo-2 phosphatase inhibitors | 尼坎治疗公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240239799-A1 | (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2024-07-18 | — | — | US | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11459340-B2 | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | ALOX5AP 3185/4885FEN1 3339/4885F2RL3 4017/4885 |
| US-11459340-B2 | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors | SRC, PTPRCAP, PTPN2 | ALOX5AP 2645/4885FEN1 3388/4885F2RL3 4072/4885 |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | ALOX5AP 3185/4885FEN1 3339/4885F2RL3 4017/4885 |
| US-20240239799-A1 | (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER | PTPN1, PTPN5, PTPRJ | ALOX5AP 1171/4885FEN1 1113/4885F2RL3 3993/4885 |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | ALOX5AP 3185/4885FEN1 3339/4885F2RL3 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.